As the First-To-File, Lupin is Eligible for 180-Day Generic Exclusivity

MUMBAI, India and NAPLES, Fla., Nov. 3, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Raltegravir Tablets USP, 600 mg in the United States following the approval from the U.S. FDA for its Abbreviated New Drug Application.